Again, it is important to note (i) the variations in immune-checkpoint inhibitor treatment regiments (single vs. combined anti-CTLA-4 and anti-PD-1/PD-L1 vs. sequential combined anti-CTLA-4 and anti-PD-1/PD-L1 immuno-checkpoint inhibition), (ii) the various antibodies used to detect tumor PD-L1 status, (iii) the tumor type (predominantly cutaneous melanoma as opposed to mucosal and/or acral) and (iv) the small size of metastases when taking our data into account. The gene discussed is PDCD1; the disease is neoplasm.